Episurf Medical’s Episealer® procedure and products are approved for payment by the U.K. Spire Hospitals and the Dutch health insurance companies, VGZ and Multiorg.
Further, the Belgium reimbursement authority RIZIV (The National Institute for Health and Disability Insurance) approved the Episealer Femoral Twin implant, thus clearning the entire portfolio (Condyle Solo, Trochlea Solo and Femoral Twin) for payment by the Belgium authority.
This activity supports Episurf’s plan to achieve private health sector reimbursement. Episurf’s patient-specific implants and Epiguide® drill guides are designed to treat localized cartilage injury in joints.
Source: Episurf Medical AB
Episurf is prepping for U.S. market entry. Experien Group has recommended a pre-510(k) submission meeting with FDA to discuss their technology, proposed indications for use and proposed performance testing.
Episurf Medical's Episealer® procedure and products are approved for payment by the U.K. Spire Hospitals and the Dutch health insurance companies, VGZ and Multiorg.
Further, the Belgium reimbursement authority RIZIV (The National Institute for Health and Disability Insurance) approved the Episealer Femoral Twin implant, thus clearning the...
Episurf Medical’s Episealer® procedure and products are approved for payment by the U.K. Spire Hospitals and the Dutch health insurance companies, VGZ and Multiorg.
Further, the Belgium reimbursement authority RIZIV (The National Institute for Health and Disability Insurance) approved the Episealer Femoral Twin implant, thus clearning the entire portfolio (Condyle Solo, Trochlea Solo and Femoral Twin) for payment by the Belgium authority.
This activity supports Episurf’s plan to achieve private health sector reimbursement. Episurf’s patient-specific implants and Epiguide® drill guides are designed to treat localized cartilage injury in joints.
Source: Episurf Medical AB
Episurf is prepping for U.S. market entry. Experien Group has recommended a pre-510(k) submission meeting with FDA to discuss their technology, proposed indications for use and proposed performance testing.
You are out of free articles for this month
Subscribe as a Guest for $0 and unlock a total of 5 articles per month.
You are out of five articles for this month
Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.